Impact of COVID-19 infections on hemodialysis patients in the province of Blida, Algeria.

ABSTRACT

Patients on hemodialysis are a group at risk for infection with SARS-CoV-2 due to impaired immunity. Our knowledge of the specific characteristics of the disease in this population is limited. Our study aims to improve our understanding of diagnostic, therapeutic, and prognostic aspects of this disease. Seventy hemodialysis patients tested by RT-PCR positive for SARS-CoV-2 were hospitalized in the nephrology department from April 1 to September 30, 2020. The patients' average age was 60.3 ± 15.0 years (18 - 88 years); including 39 patients (55.7%) were male. The comorbidities found were hypertension (67.1%), diabetes (32.9%), and obesity (17.1%). Our patients' laboratory abnormalities were leukopenia (15.7%) and lymphopenia in 60% of patients. The pulmonary involvement on computed tomography was classified as moderate (74.3%) and severe in 24.3% of cases. Fifty-seven patients (78.6%) had received hydroxychloroquine and 14 patients (20%) antivirals therapy. We recorded 82.9% of cured patients and 17.1% of deaths in our series. The death occurred 8 ± 7.5 days (1 - 25 days) of hospitalization. Hemodialysis centres are high-risk places, and hemodialysis patients are considered a vulnerable population during the COVID-19 pandemic. They should be given special attention.